STOCK TITAN
  1. Home
  2. MBGRF

Moberg Pharma (MBGRF) Stock Price, News & Analysis

MBGRF
Published by Stock Titan Data refreshed

What Changed

Company Description

This page collects what Stock Titan holds for MBGRF, including price data and latest news.

Stock Performance

Chart
$—
-
-
Last updated:
-
Performance 1 year
-
Market Cap
-
Shares outstanding

Latest News

View All
—

Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU

clinical trial
—

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

clinical trial
—

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

—

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

—

MOB-015 is recommended for approval in EU: Moberg Pharma

—

Moberg Pharma and Padagis sign agreement for MOB-015 in Israel

—

European marketing authorization application for MOB-015 submitted

—

The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration application

—

Moberg Pharma receives approval from the EMA's Paediatric Committee

—

Moberg Pharmas Year-end report 2020

Moberg Pharma has 10 recent news articles. Key topics include clinical trial. View all MBGRF news →

SEC Filings

View All

No SEC filings available for MBGRF.